A MEDICINE COMPANY


ELI LILLY AND COMPANY
Q2 2025 EARNINGS CALL



Agenda

Introduction and Key Events
Dave Ricks, Chair and Chief Executive Officer

Q2 2025 Financial Results
Lucas Montarce, Chief Financial Officer

R&D Update
Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

Question & Answer Session

Safe Harbor Provision and Other Information

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated.

The company undertakes no duty to update forward-looking statements except as required by applicable law.

Q2 2025 Summary

Deliver Revenue Growth

Delivered robust **revenue growth of 38%** driven by **Key Products**[1]

Lilly U.S. incretin analogs **share of market** increased to **57.0%** of total prescriptions, with **market growing 41%** versus prior year

Raised midpoint of revenue guidance by **$1.5 billion** for the full year

Invest in Future Innovation

Produced 1.6x more saleable incretin doses in 1H 2025 compared to 1H 2024

Closed acquisitions of **SiteOne Therapeutics** and **Verve Therapeutics** to **expand pipeline**

Speed Life-Changing Medicines

Orforglipron delivered **weight loss of more than 27 lbs** in ATTAIN-1

Mounjaro **demonstrated cardiovascular protection in** SURPASS-CVOT

Jaypirca **met primary endpoint in H2H Phase 3 trial** versus ibrutinib in CLL/SLL

[1] Key products include Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound
Note: Revenue growth rates reflect change vs. Q2 2024

Strategic Deliverables

Deliver Revenue Growth

TOTAL REVENUE $15.6B 38% ⬆

KEY PRODUCT REVENUE $10.4B 80% ⬆

Invest in Future Innovation

RESEARCH & DEVELOPMENT

$3.3B

23% ⬆

INCRETIN SUPPLY

+1.6x

Saleable doses produced in 1H 2025 vs. 1H 2024

Invest in Current Portfolio

MARKETING, SELLING & ADMINISTRATIVE $2.8B 30% ⬆

NON-GAAP EARNINGS PER SHARE $6.31 61% ⬆

Speed Life-Changing Medicines

APPROVALS / LAUNCHES

- Received positive CHMP opinion for Kisunla in the EU
- FDA approved updated label for Kisunla with new dosing in early symptomatic Alzheimer's disease
- Launched 12.5 mg and 15.0 mg single-dose Zepbound vials exclusively through LillyDirect

kisunla (donanemab-azbt) injection

once weekly zepbound (tirzepatide) injection

STUDY RESULTS

- Orforglipron delivered weight loss of more than 27 lbs (12.4%) in ATTAIN-1 and showed safety and tolerability consistent with injectable GLP-1 therapies
- Mounjaro met the primary objective of non-inferiority versus Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight
- Jaypirca met its primary endpoint in a H2H Phase 3 trial versus ibrutinib in CLL/SLL

Return Capital to Shareholders

$1.3B **DISTRIBUTED VIA DIVIDENDS**

$0.7B **DISTRIBUTED IN SHARE REPURCHASES**

Note: Total revenue, key product revenue, research and development, marketing, selling and administrative, and Non-GAAP EPS growth rates reflect change vs. Q2 2024

Q2 Key Income Statement Measures (unaudited)

Dollars in millions; except per share data

Q2 2025

	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
TOTAL REVENUE	**$15,558**	$ -	**$15,558**	38%
GROSS MARGIN	**84.3%**	0.7 pp	**85.0%**	3.0pp
TOTAL OPERATING EXPENSE	**$6,243**	$ -	**$6,243**	25%
OPERATING INCOME	**$6,867**	$122	**$6,989**	63%
OTHER INCOME (EXPENSE)	**$(91)**	$(98)	**$(189)**	NM
EFFECTIVE TAX RATE	**16.5%**	--	**16.5%**	--
NET INCOME	**$5,661**	$18	**$5,679**	60%
EPS	**$6.29**	$0.02	**$6.31**	61%
Acquired IPR&D Charge per share[1]	**$0.14**	**$ -**	**$0.14**	**0%**

[1] Acquired IPR&D (in-process research and development) charge of $154 million (pre-tax). Numbers may not add due to rounding; NM = not meaningful

Performance Margin[2]	**45.1%**		**45.9%**	**+6.6pp**

[2] The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and asset impairment, restructuring and other special charges divided by revenue
Note: The Non-GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables on slide 20

Price/Rate/Volume Effect on Revenue

Dollars in millions

Q2 2025

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$10,814	(8)%	-	46%	38%	38%
EUROPE	$2,574	(2)%	6%	79%	83%	77%
JAPAN	$521	(0)%	5%	7%	13%	7%
CHINA	$466	3%	(1)%	16%	18%	19%
REST OF WORLD	$1,182	(0)%	(1)%	(0)%	(2)%	(1)%
TOTAL REVENUE	**$15,558**	**(6)%**	**1%**	**42%**	**38%**	**37%**

Dollars in millions

YTD 2025

	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$19,304	(8)%	-	50%	43%	43%
EUROPE	$4,963	(5)%	0%	79%	74%	74%
JAPAN	$923	(1)%	1%	11%	12%	11%
CHINA	$917	2%	(1)%	18%	19%	20%
REST OF WORLD	$2,180	0%	(3)%	6%	4%	7%
TOTAL REVENUE	**$28,286**	**(6)%**	**(0)%**	**47%**	**41%**	**41%**

Numbers may not add due to rounding

CER = price change + volume change

Q2 2025 Update on Key Products



Key Product Highlights:

MOUNJARO
U.S. type 2 diabetes incretin analogs TRx SOM 42% and NBRx SOM 50% at end of Q2 2025

Increased TRx and NBRx SOM by 3pp and 5pp, respectively, vs. end of Q1 2025

International markets becoming a meaningful growth driver

ZEPBOUND
U.S. branded anti-obesity TRx SOM 66% and NBRx SOM 68% at end of Q2 2025

TRx SOM increased by 5pp and NBRx SOM decreased by 6pp vs. end of Q1 2025

NBRx SOM impacted by loss of access on CVS template plans effective 7/1/25

VERZENIO
U.S. TRx SOM 40% at end of Q2 2025
U.S. TRx grew 4% vs. Q2 2024
International volume grew 18% vs. Q2 2024

JAYPIRCA
Q2 2025 sales of $123M and TRx increased 85% vs. Q2 2024

EBGLYSS
Q2 2025 sales of $87M and published results of ADmirable 24-week study in adults and adolescents with skin of color and atopic dermatitis

OMVOH
Q2 2025 sales of $75M and citrate-free formulation available

KISUNLA
Q2 2025 sales of $49M and currently launched in 13 countries OUS

U.S. Incretin Analogs Market



Source: IQVIA weekly NPA total prescriptions, weekly data June 27, 2025; Incretin analogs market includes: injectable GLP-1s, oral GLP-1s and GLP-1/GIP dual agonists

Incretin Analogs Market Key Highlights:

U.S. market grew 41% in Q2 vs. prior year and 13% vs. Q1 2025

Lilly share of market increased to 57.0%, +3.8pp vs. prior quarter

Launched 12.5 mg and 15.0 mg single-dose Zepbound vials via LillyDirect

Zepbound CVS template plans access change as of 7/1/25

Zepbound has confirmed open access at 2 of 3 major PBMs

Capital Allocation

$ in billions

1H 2025 Capital Allocation



* After tax

** Includes development milestones, closed acquisitions and cash outflows associated with equity investments

2025 Guidance

	Prior	Updated	Comments
REVENUE	$58.0 – $61.0 billion	$60.0 – $62.0 billion	Strength of underlying business and updated foreign exchange rate expectations
PERFORMANCE MARGIN[1]			
(GAAP)	40.5% – 42.5%	42.0% – 43.5%	Increased to reflect updated revenue growth expectations
(NON-GAAP)	41.5% – 43.5%	43.0% – 44.5%	
OTHER INCOME/(EXPENSE)			
(GAAP)	$(850) – $(750) million	$(750) – $(650) million	Decrease in net losses on investments in equity securities
(NON-GAAP)	$(700) – $(600) million	Unchanged	
TAX RATE			
(GAAP)	Approx. 17%	Approx. 19%	Reflects anticipated third quarter charge as a result of recently enacted U.S. tax legislation (GAAP)
(NON-GAAP)	Approx. 17%	Unchanged	
EARNINGS PER SHARE[2]			
(GAAP)	$20.17 – $21.67	$20.85 – $22.10	
(NON-GAAP)	$20.78 – $22.28	$21.75 – $23.00	

[1] The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative and asset impairment, restructuring and other special charges divided by revenue
[2] 2025 assumes shares outstanding of approximately 899.6 million
FX assumptions of 1.14 (Euro), 149 (Yen) and 7.2 (Yuan)

SURPASS-CVOT Topline Results

Cardiovascular Protection (Primary Outcome)

- Tirzepatide demonstrated non-inferiority vs. dulaglutide with an 8%[1] lower rate of MACE-3 events and a 16%[2,3] lower rate of all-cause death
- Tirzepatide reduced the risk of MACE-3 events by 28% and all-cause mortality by 39% vs. putative placebo[4]

HbA1c Control

- Tirzepatide delivered a 0.83%[3,6] greater reduction in A1C from mean baseline vs. dulaglutide at 36 months

Weight Loss

- Tirzepatide demonstrated a 6.78 kg[3,5] (14.95 lbs) greater reduction in body weight vs. dulaglutide at 36 months

Kidney Protection

- Tirzepatide slowed eGFR decline by 3.54[3,7] ml/min/1.73 m^2 vs. dulaglutide in participants with high or very-high risk of CKD[8] at 36 months

The safety of tirzepatide and dulaglutide were generally consistent with their established profiles

[1] Hazard ratio: 0.92, 95.3% CI: 0.83 to 1.01; [2] Hazard ratio: 0.84, 95.0% CI: 0.75 to 0.94; [3] Not controlled for multiplicity-adjusted type 1 error rate;
[4] Based on a pre-specified indirect comparison analysis of matched patient-level data from the REWIND and SURPASS-CVOT studies; [5] Estimated treatment difference: -7.1%, 95.0% CI: -7.4 to -6.8; [6] 95.0% CI: -0.88 to -0.78;
[7] 95.0% CI: 2.57 to 4.50; [8] Chronic kidney disease

Orforglipron ATTAIN-1 Topline Results



[1] Superiority test was adjusted for multiplicity

Key Highlights:

Once-daily oral pill reduced weight by an average of 27.3 lbs (12.4%) at the highest dose

Approximately 60% of participants taking the highest dose of orforglipron achieved body weight reductions of greater than or equal to 10%[1]

Approximately 40% of participants taking the highest dose of orforglipron achieved body weight reductions of greater than or equal to 15%[1]

Lilly plans to submit orforglipron to regulatory agencies by year-end

Orforglipron ATTAIN-1 Safety & Tolerability

Discontinuation Rates due to Adverse Events



Tolerability Data

	Placebo	Orforglipron 6 mg	Orforglipron 12 mg	Orforglipron 36 mg
Nausea (%)	10.4%	28.9%	35.9%	33.7%
Constipation (%)	9.3%	21.7%	29.8%	25.4%
Diarrhea (%)	9.6%	21.0%	22.8%	23.1%
Vomiting (%)	3.5%	13.0%	21.4%	24.0%

The overall safety profile of orforglipron in ATTAIN-1 was consistent with the established GLP-1 receptor agonist class. Treatment discontinuations due to adverse events were low and consistent with the injectable GLP-1 class.

Lilly Select NME and NILEX Pipeline

August 5, 2025

NME
NILEX

UPDATES SINCE APRIL 29, 2025
REMOVAL
ADDITION OR MILESTONE ACHIEVED

PHASE 1

- PTK7 ADC — *Cancer*
- NAV 1.8 INH (STC-004) — *Pain*
- PCSK9 EDITOR (VERVE-102) — *ASCVD*
- GGG TRI-AGONIST III — *CMH*
- GS INSULIN RECEPTOR AGONIST II — *Diabetes*
- TARGETS UNDISCLOSED — *Nine Additional NMEs*
- ANGPTL3 EDITOR (VERVE-201) — *ASCVD*
- SNCA siRNA — *Neurodegeneration*
- VEPUGRATINIB (FGFR3 SELECTIVE) — *Cancer*
- SARM1 INHIBITOR — *Neurodegeneration*
- SMARCA2 (BRM) — *Cancer*
- PI3Kα INH (STX-478) — *Cancer*
- PNPLA3 siRNA — *MASLD*
- NECTIN-4 ADC 2 — *Cancer*
- PAN KRAS — *Cancer*
- MAPT siRNA — *Neurodegeneration*
- NECTIN-4 ADC 1 — *Cancer*
- LA-ANP — *Heart Failure*
- MACUPATIDE — *CMH*
- INTEGRIN α5β1 — *CMH*
- KRAS G12D — *Cancer*
- GIPR AGONIST LA — *CMH*
- GS INSULIN RECEPTOR AGONIST — *Diabetes*
- FXR AG (FXR314) — *Immunology*
- GIP/GLP-1 COAGONIST III — *CMH*
- AT2R ANTAGONIST — *Pain*
- FRa ADC — *Cancer*
- [Ac-225]-PSMA-62 — *Prostate Cancer*
- ANTI-VEGF GENE THERAPY — *Vestibular Schwannoma*

PHASE 2

- TIRZEPATIDE — *Higher Doses*
- TIRZEPATIDE — *MASLD*
- GBA1 GENE THERAPY — *Gaucher Disease Type 1*
- MORF-057 — *Crohn's Disease*
- CD19 ANTIBODY — *Rheumatoid Arthritis*
- ELTREKIBART — *Ulcerative Colitis*
- SOLBINSIRAN — *CVD*
- NISOTIROSTIDE — *Diabetes*
- P2X7 INHIBITOR — *Pain*
- SIMEPDEKINRA — *Psoriasis*
- OCADUSERTIB — *Rheumatoid Arthritis*
- OTOF GENE THERAPY — *Hearing Loss*
- MUVALAPLIN — *ASCVD*
- NAPERIGLIPRON (GLP-1R NPA II) — *Obesity*
- MEVIDALEN — *AD Symptomatic*
- MORF-057 — *Ulcerative Colitis*
- GRN GENE THERAPY — *Frontotemporal Dementia*
- MAZDUTIDE[1] — *Obesity*
- EPIREGULIN Ab — *Pain*
- GBA1 GENE THERAPY — *Parkinson's Disease*
- ELORALINTIDE — *Obesity*
- ELTREKIBART — *Hidradenitis Suppurativa*
- BIMAGRUMAB — *Obesity*
- CD19 ANTIBODY — *Multiple Sclerosis*

PHASE 3

- RETATRUTIDE — *CLBP*
- TIRZEPATIDE — *Type 1 Diabetes*
- OLOMORASIB *Adj KRAS G12C+ NSCLC (unresected)*
- ORFORGLIPRON — *Hypertension*
- TIRZEPATIDE — *CV Outcomes*
- TIRZEPATIDE — *MMO*
- RETATRUTIDE — *Diabetes*
- SELPERCATINIB — *Adjuvant RET+ NSCLC*
- PIRTOBRUTINIB — *R/R MCL Monotherapy*
- RETATRUTIDE — *CV / Renal Outcomes*
- PIRTOBRUTINIB — *1L CLL Monotherapy*
- PIRTOBRUTINIB — *R/R CLL Combination*
- ORFORGLIPRON — *Diabetes*
- ORFORGLIPRON — *Obstructive Sleep Apnea*
- OLOMORASIB *1L KRAS G12C+ NSCLC (PD-L1 high)*
- OLOMORASIB *Adj KRAS G12C+ NSCLC (resected)*
- LEBRIKIZUMAB — *AR (perennial allergens)*
- LEBRIKIZUMAB — *CRSwNP*
- IXEKIZUMAB + TIRZEPATIDE — *PsA*
- IXEKIZUMAB + TIRZEPATIDE — *Psoriasis*
- DONANEMAB *Preclinical Alzheimer's Disease*
- IMLUNESTRANT — *Adjuvant Breast Cancer*
- RETATRUTIDE — *Obesity, OA, OSA*
- ABEMACICLIB — *MBC Sequencing*
- ORFORGLIPRON — *Obesity*
- REMTERNETUG — *Alzheimer's Disease*
- LEPODISIRAN — *ASCVD*
- OLOMORASIB *1L KRAS G12C+ NSCLC (All PD-L1)*

REG REVIEW

- TIRZEPATIDE — *Heart Failure pEF*
- INSULIN EFSITORA ALFA — *Diabetes*
- IMLUNESTRANT — *ER+ HER2- mBC*

APPROVED

REMOVALS

- ITACONATE MIMETIC — *Immunology*
- SCAP siRNA — *MASLD*
- KV1.3 ANTAGONIST — *Psoriasis*
- MAZISOTINE — *Pain*

[1]China development with Innovent for Obesity (approved) and T2DM (reg review)

Potential Key Events 2025

NEW SINCE LAST UPDATE

PHASE 3 INITIATIONS

- ✓+ Orforglipron for hypertension and overweight or obesity
- ✓+ Olomorasib for resected adjuvant NSCLC[1]
- Muvalaplin for ASCVD[2]
- ✓+ Retatrutide for chronic low back pain and overweight or obesity
- ✓+ Olomorasib for unresected NSCLC[1]
- ✓+ Tirzepatide for type 1 diabetes
- Orforglipron for OA[3] pain of the knee and overweight or obesity
- Retatrutide and Tirzepatide for MASLD[4]

REGULATORY SUBMISSIONS

- Insulin efsitora alfa for type 2 diabetes [US / EU ✓+ / J]
- Orforglipron for obesity [US/EU/J]
- Tirzepatide for cardiovascular outcomes [US]
- ✓+ Pirtobrutinib CLL full approval [US ✓+]
- Pirtobrutinib for 1L CLL [US/EU]
- ✓+ Tirzepatide for Pediatric and Adolescent type 2 diabetes [US ✓+/ EU ✓+]

PHASE 3 DATA DISCLOSURES

- Orforglipron for obesity [ATTAIN-1 ✓+ / 2]
- Orforglipron for type 2 diabetes [ACHIEVE-1 ✓+ /2/3/5]
- ✓+ Tirzepatide cardiovascular outcomes [SURPASS-CVOT]
- Pirtobrutinib 1L CLL vs. BR[5] [BRUIN CLL-313]
- ✓+ Pirtobrutinib 1L CLL vs. ibrutinib [BRUIN CLL-314]
- Retatrutide for OA[3] pain of the knee and overweight or obesity [TRIUMPH-4]

REGULATORY ACTIONS

- ✓+ Mirikizumab for Crohn's disease [US ✓+ / EU ✓+ / J ✓+]
- Tirzepatide for HFpEF [US ✓- /EU]
- Imlunestrant ER+, HER2- mBC [US/J]
- Pirtobrutinib for CLL full approval [US / EU ✓+ / J]
- Donanemab for early Alzheimer's disease [EU]

[1] Non-small cell lung cancer; [2] Atherosclerotic cardiovascular disease; [3] Osteoarthritis; [4] Metabolic dysfunction-associated steatotic liver disease; [5] Bendamustine plus Rituximab

Supplemental Slides

2025 Income Statement – Reported

Dollars in millions; except per share data

	Q2 2025	Change
TOTAL REVENUE	**$15,558**	38%
GROSS MARGIN	**84.3%**	3.5pp
TOTAL OPERATING EXPENSE*	**$6,243**	15%
OPERATING INCOME	**$6,867**	85%
OPERATING MARGIN	**44.1%**	11.2pp
OTHER INCOME (EXPENSE)	**$(91)**	(54%)
EFFECTIVE TAX RATE	**16.5%**	0.9pp
NET INCOME	**$5,661**	91%
EPS	**$6.29**	92%

* Includes research and development expense; marketing, selling and administrative; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)
NM = not meaningful

EPS Reconciliation

	Q2 2025	Q2 2024	% Change
EARNINGS PER SHARE (REPORTED)	$6.29	$3.28	92%
ASSET IMPAIRMENT, RESTRUCTURING AND OTHER SPECIAL CHARGES	–	0.38	NM
NET LOSSES (GAINS) ON INVESTMENTS IN EQUITY SECURITIES	(0.09)	0.14	(164%)
AMORTIZATION OF INTANGIBLE ASSETS	0.11	0.12	(8%)
EARNINGS PER SHARE (NON-GAAP)	$6.31	$3.92	61%
ACQUIRED IPR&D	$0.14	$0.14	0%

Numbers may not add due to rounding; see slide 21 for more details on these adjustments; NM = not meaningful

Q2 Non-GAAP Adjustments

Q2 2025 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $121.8 million (pre-tax), or $0.11 per share (after-tax)
- net gains on investments in equity securities totaling $98.4 million (pre-tax), or ($0.09) per share (after-tax)

Q2 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $139.1 million (pre-tax), or $0.12 per share (after-tax)
- net losses on investments in equity securities totaling $147.7 million (pre-tax), or $0.14 per share (after-tax).
- asset impairment, restructuring and other special charges totaling $435.0 million (pre-tax), or $0.38 per share (after-tax).

Q2 2025 Mounjaro Sales Increased $2.1B

$ in Millions

U.S. sales were $3.3 billion
International sales were $1.9 billion



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 27, 2025; RA = rolling average
TRx data is representative of the injectable incretin type 2 diabetes market

Q2 2025 Zepbound Sales Increased $2.1B

$ in Millions

U.S. sales were $3.4 billion
International sales were $1.5 million[1]



U.S. TRx SOM and Market Volume



[1] Japan and Canada marketing authorization approved for obesity under the brand name Zepbound

Source: IQVIA NPA TRx 3MMA, weekly data June 27, 2025; RA = rolling average
TRx data is representative of the branded anti-obesity market

Q2 2025 Verzenio Sales Increased 12%

$ in Millions

U.S. sales increased 8%
International sales increased 19%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 27, 2025; RA = rolling average

Select Trials – Donanemab

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04437511	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)	Apr 2023	Aug 2025
NCT05738486	Alzheimer's Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	1100	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	May 2024	May 2025
NCT05508789	Alzheimer's Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)	May 2028	July 2028
NCT05026866	Alzheimer's Disease	A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2996	Time to clinical progression as measured by Clinical Dementia Rating - Global Score (CDR-GS)	Nov 2027	Nov 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Imlunestrant

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04975308	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	874	Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)	Jun 2024	Aug 2027
NCT05514054	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	8000	Invasive Disease-Free Survival (IDFS)	Oct 2027	Mar 2032

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lebrikizumab

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05559359	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	360	Percentage of Participants with an Investigator Global Assessment (IGA) score 0 or 1 and a Reduction ≥2 points from Baseline	Dec 2025	Dec 2026
NCT05735483	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	310	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Dec 2027	Apr 2029
NCT06280716	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (ADvance-Asia)	3	301	Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) ≥75% Reduction in EASI Score for Mono Cohort	Sep 2025	Aug 2026
NCT06339008	Perennial Allergic Rhinitis (PAR)	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)	3	450	Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16	Oct 2025	Feb 2027
NCT06921759	Atopic Hand and Foot Dermatitis	A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (ADtouch)	3	206	Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline	Jul 2026	Sep 2026
NCT06338995	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	3	510	Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity	Oct 2026	Feb 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Lepodisiran

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06292013	Atherosclerotic Cardiovascular Disease (ASCVD)[1]	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	3	16700	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029

[1] Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Mirikizumab

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	778	Percentage of Participants Achieving Endoscopic Response	Nov 2024	Dec 2026
NCT06937099	Crohn's Disease	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT-CD)	3	290	Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction	May 2028	May 2028
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3)	3	1063	Percentage of Participants in Clinical Remission	Jul 2026	Dec 2027
NCT06937086	Ulcerative Colitis	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC)	3	350	Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction	Apr 2028	Apr 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Olomorasib

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06119581	Carcinoma, Non-Small-Cell Lung	A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)	3	1016	Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)	Oct 2026	Oct 2029
NCT06890598[1]	Carcinoma, Non-Small-Cell Lung	Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)	3	700	Part A: Disease-Free Survival (DFS) by Investigator Assessment	May 2029	Feb 2032
NCT04956640[2]	Carcinoma, Non-Small-Cell Lung	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	1|2	540	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy	Apr 2027	Apr 2027

[1] Also lists AstraZeneca; [2] Also lists Merck Sharp & Dohme LLC

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06109311	Type 2 Diabetes	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)	3	520	Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2025	Sep 2025
NCT06045221	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3)	3	1576	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2025	Sep 2025
NCT05803421	Type 2 Diabetes	A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)	3	2749	Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]	Sep 2025	Jan 2026
NCT06192108	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)	3	888	Change from Baseline in Hemoglobin A1c: (HbA1c)	Sep 2025	Sep 2025
NCT06948422	Hypertension	A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension)	3	974	Number of Participants Allocated to Each ISA	Sep 2027	Sep 2027
NCT05931380	Obesity	A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J)	3	236	Mean Percent Change in Body Weight	Jun 2025	July 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05869903	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3000	Mean Percent Change from Baseline in Body Weight	Jul 2025	Jul 2027
NCT05872620	Obesity	A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)	3	1500	Mean Percent Change from Baseline in Body Weight	Aug 2025	Aug 2025
NCT06584916	Obesity	A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)	3	300	Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5	Jan 2026	Jan 2026
NCT06672939	Obesity	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities	3	125	Percent Change from Baseline in Body Mass Index (BMI)	Feb 2027	Mar 2027
NCT06972472	Obesity	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	3	600	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2027	Aug 2027
NCT06972459	Obesity	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	3	600	Percent Change from Baseline in Body Weight	Jan 2027	Aug 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Orforglipron (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06649045	OSA	A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA)	3	600	Change from Baseline in Apnea-Hypopnea Index (AHI)	Nov 2026	Jan 2027
NCT06824051	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight	1	120	Percent Change from Baseline in Visceral Adipose Tissue (VAT)	Dec 2025	Dec 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Pirtobrutinib

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	238	Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)	Aug 2023	May 2027
NCT05023980	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	309	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Jul 2025	Aug 2026
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Apr 2026	Jan 2027
NCT05254743	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL – 314)	3	662	Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1	Jun 2025	Jan 2028
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Jan 2027	Apr 2028
NCT06721013	Immune Thrombocytopenia (ITP)	A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia	1|2	58	Ph. 1 -Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2026	Feb 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Remternetug

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05463731	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)	3	1667	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo	Apr 2024	Mar 2026
NCT06653153	Alzheimer's Disease	A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)	3	1400	Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)	Apr 2029	Oct 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05929066	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)	3	2300	Percent Change From Baseline in Body Weight	Apr 2026	May 2026
NCT05929079	Obesity	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)	3	1000	Percent Change from Baseline in Body Weight	May 2026	May 2026
NCT05882045	Obesity	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)	3	1800	Percent Change from Baseline in Body Weight	Apr 2026	May 2026
NCT05931367	Obesity	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)	3	405	Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score	Dec 2025	Dec 2025
NCT06383390	Obesity	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES)	3	10000	Time to First Occurrence of Composite Endpoints	Feb 2029	Feb 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06662383	Obesity	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)	3	800	Percent Change from Baseline in Body Weight	Dec 2026	Dec 2026
NCT06859268	Obesity	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6)	3	643	Percent Change from Baseline in Body Weight	Apr 2028	Apr 2028
NCT06354660	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)	3	480	Change from Baseline in Hemoglobin A1c (HbA1c)	Jan 2026	Feb 2026
NCT06297603	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2026	Oct 2026
NCT06260722	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in Hemoglobin A1c (HbA1c)	Aug 2026	Jan 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retatrutide (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT07035093	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain	3	586	Percent Change from Baseline in Body Weight | Change from Baseline in Pain Intensity Per Numeric Rating Scale	Sep 2027	Sep 2027
NCT05936151	Chronic Kidney Disease	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	2	146	Change from Baseline in Glomerular Filtration Rate (mGFR)	Nov 2025	Nov 2025
NCT06982846	Type 2 Diabetes Mellitus	A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia	1	78	Time-to-Event of Recovery of Plasma Glucose (PG) Concentration from 48 Milligram per Deciliter (48 mg/dL) to 70 mg/dL (tPG_nadir-70 mg/dL)	May 2026	May 2026
NCT06982859	Diabetes Mellitus	A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus	1	95	Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo	Nov 2026	Nov 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Retevmo

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Feb 2026
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (With Pembrolizumab)	May 2023	Jun 2026
NCT03157128	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1|2	857	Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment	Feb 2025	Feb 2026
NCT04819100	Carcinoma, Non-Small-Cell Lung	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	152	Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population	May 2026	May 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Taltz

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06588283	Psoriasis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO)	3	250	Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction	Dec 2025	May 2026
NCT06588296	Psoriatic Arthritis	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA)	3	250	Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction	Apr 2026	Aug 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Tirzepatide

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06047548	Obesity	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)	3	400	Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period	May 2026	May 2026
NCT06075667	Obesity	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS)	3	150	Percent Change from Baseline in Body Mass Index (BMI)	May 2026	Jul 2029
NCT06439277	Obesity	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	3	300	Percent Change from Baseline in Body Mass Index (BMI)	May 2027	Jun 2027
NCT05556512	Obesity	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)	Oct 2027	Oct 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Tirzepatide (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06037252	Type 2 Diabetes	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	350	Percent Change From Baseline in Body Weight	Jan 2026	Oct 2026
NCT05536804	CKD	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D	Sep 2026	Oct 2026
NCT06914895	Type 1 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	3	905	Change from Baseline in Hemoglobin A1c (HbA1c)	May 2027	May 2027
NCT06962280	Type 1 Diabetes	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	3	465	Change from Baseline in Hemoglobin A1c (HbA1c)	Apr 2027	Dec 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Verzenio

Source: clinicaltrials.gov, July 28, 2025

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997[1]	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival (IDFS)	Mar 2020	May 2029
NCT05169567	Breast Neoplasm	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch)	3	368	Progression-Free Survival (PFS)	Feb 2024	Feb 2026

[1] Also lists NSABP Foundation Inc

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Bimagrumab	NCT06643728	Obesity	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	2	240	Percent Change from Baseline in Body Weight	Apr 2026	Jan 2027
Bimagrumab	NCT06901349	Obesity	A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes	2	180	Percent Change from Baseline in Body Weight	Oct 2026	Jan 2027
Bimagrumab	NCT07030127	Healthy	A Study of LY3985863 in Healthy Participants	1	24	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2026	Apr 2026
Eloralintide	NCT06230523	Obesity	A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight	2	263	Percent Change from Baseline in Body Weight	May 2025	Sep 2025
Eloralintide	NCT06603571	Obesity	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	2	350	Percent Change from Baseline in Body Weight	Jun 2026	Aug 2026
Eloralintide	NCT06916091	Obesity	A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight	1	36	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2025	Sep 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
GIP/GLP-1 Coagonist III	NCT06606106	Healthy	A Study of LY3537031 in Overweight, Obese, and Healthy Participants	1	302	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	Jul 2026	Jul 2026
GS Insulin Receptor Agonist	NCT06280703	Healthy	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)	1	70	Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Oct 2025	Oct 2025
LA-ANP	NCT06148272	Healthy	A Study of LY3971297 in Healthy Participants	1	225	Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2025	Dec 2025
Macupatide	NCT06557356	Obesity	A Study of LY3532226 in Participants With Obesity	1	129	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Nov 2025	Nov 2025

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Cardiometabolic Health

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Nisotirostide	NCT06897475	Type 2 Diabetes	A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	2	240	Change from Baseline in Hemoglobin A1c (HbA1c)	Dec 2026	Jan 2027
Naperiglipron (GLP-1R NPA II)	NCT06683508	Obesity	A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight	2	275	Percent Change from Baseline in Body Weight	Apr 2026	Sep 2026
PNPLA3 siRNA	NCT05395481	Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)	A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	1	176	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration	Oct 2026	Oct 2026
ANGPTL3 EDITOR (VERVE-201)	NCT06451770	Hypercholesterolemia	Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia	1	36	Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Mar 2027	Mar 2027
PCSK9 EDITOR (VERVE-102)	NCT06164730	Heterozygous Familial Hypercholesterolemia	A Study of VERVE-102 in Patients with Familial Hypercholesterolemia or Premature Coronary Artery Disease	1	36	Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Aug 2026	Aug 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Immunology

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
CD19 Antibody	NCT06220669	Multiple Sclerosis	A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	2	200	Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions	Aug 2027	Aug 2028
CD19 Antibody	NCT06859294	Rheumatoid Arthritis	A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis	2	40	Change from Baseline in Disease Activity Score - High-Sensitivity C-Reactive Protein (DAS28 - hsCRP)	Feb 2026	Sep 2026
SIMEPDEKINRA (DC-853)	NCT06602219	Plaque Psoriasis	A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis	2	220	Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75	Jul 2025	Aug 2025
Eltrekibart	NCT06046729	Hidradenitis Suppurativa	A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	350	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Oct 2025	Jul 2026
Eltrekibart	NCT06598943	Ulcerative Colitis	A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	2	140	Percentage of Participants Achieving Clinical Remission	Dec 2027	Sep 2028

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Immunology (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
MORF-057	NCT05611671	Ulcerative Colitis	A Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC (EMERALD-2)	2	282	Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS)	Nov 2024	Aug 2026
MORF-057	NCT06226883	Crohn's Disease	A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)	2	210	Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD)	Nov 2026	Aug 2028
Ocadusertib[1]	NCT05848258	Rheumatoid Arthritis	An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis	2	380	Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)	Feb 2026	Jul 2026

[1] Also lists Rigel Pharmaceuticals

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Neurodegeneration

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Anti-VEGF Gene Therapy	NCT06517888	Vestibular Schwannoma	Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma	1|2	27	AEs with relationship to the investigational medicinal product and/or to the administration procedure (including the delivery device)	Aug 2029	Aug 2029
GBA1 Gene Therapy	NCT04127578	Parkinson's Disease	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1|2	20	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Dec 2030	Dec 2030
GBA1 Gene Therapy	NCT05487599	Gaucher Disease	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	1|2	15	Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Oct 2030	Oct 2030
GRN Gene Therapy	NCT04408625	Frontotemporal Dementia	Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)	1|2	30	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation	Apr 2030	Apr 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Neurodegeneration (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
MAPT siRNA	NCT06297590	Alzheimer's Disease	A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	1	32	Part A: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Feb 2027	Feb 2027
Mazdutide	NCT06817356	Alcohol Use Disorder	A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder	2	300	Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method	Aug 2026	Aug 2026
Mevidalen	NCT06538116	Alzheimer's Disease	A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease	2	300	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	Dec 2025	Jan 2026
OTOF Gene Therapy	NCT05821959	Sensorineural Hearing Loss, Bilateral	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1|2	14	Frequency of Adverse Events (AEs)	Oct 2028	Oct 2028
SNCA siRNA	NCT06565195	Parkinson's Disease	A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease (PROSPECT)	1	108	Incidence of Serious Adverse Events (SAEs)	May 2029	May 2029

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Oncology

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
225Ac-PSMA-62	NCT06229366	Prostate Cancer	[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)	1	142	Maximum tolerated dose (MTD), Phase 1a: Incidence of dose limiting toxicities (DLTs)	Sep 2027	Dec 2032
VEPUGRATINIB (FGFR3 SELECTIVE)	NCT05614739	Urinary Bladder Neoplasms	A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (FORAGER-1)	1	535	Phase 1a: To determine the recommended dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)	Jun 2027	Jun 2027
Fra ADC (FOLR1 ADC)	NCT06400472	Ovarian Neoplasms	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	1	360	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156, Number of participants with dose-limiting toxicities (DLTs)	Feb 2027	Apr 2027
KRAS G12D	NCT06586515	Pancreatic Ductal Adenocarcinoma	A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors (MOONRAY-01)	1	570	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Mar 2029	Mar 2029
Nectin-4 ADC 1	NCT06238479	Metastatic Solid Tumor	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (EXCEED)	1	490	Phase 1a: To determine the recommended dose of LY4101174: Number of participants with dose-limiting toxicities (DLTs)	Mar 2027	Mar 2027

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Oncology (Cont.)

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
PAN KRAS	NCT06607185	Pancreatic Ductal Adenocarcinoma	A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	1	750	Number of Participants with Dose-limiting Toxicities (DLTs)	Jan 2030	Jan 2030
SMARCA2 (BRM)	NCT06561685	Metastatic Solid Tumor	A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors	1	340	Phase 1a: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)	Oct 2027	Oct 2027
PI3Kα INH (STX-478)	NCT05768139	Breast Cancer	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors	1|2	720	Number of participants who experience at least 1 Dose Limiting Toxicity (DLT)	Feb 2027	Feb 2029
PTK7 ADC	NCT07046923	Carcinoma, Non-Small-Cell Lung	A Study of LY4175408 in Participants With Advanced Cancer	1	240	Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408	Jul 2030	Jul 2030

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Select Trials – Early Phase Pain

Source: clinicaltrials.gov, July 28, 2025

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
AT2R Antagonist	NCT07039045	Healthy	A Study of [14C]-LY4065967 in Healthy Participants	1	16	Part 1: Percentage of Total Radioactive Dose in Urine and Fecal Excretion	Sep 2025	Sep 2025
Epiregulin Ab	NCT06568042	Neuropathic Pain	Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy	2	450	Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)	Jun 2026	Sep 2026

* Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes

Trademarks

All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade names in this earnings update are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.